NanoSPharm Raises €8.3M for Prosthetic Coating Technology

A significant new venture, NanoSPharm, has officially launched, backed by an initial investment of €8.3 million. This innovative company is set to revolutionize the biomedical sector by developing and commercializing cutting-edge technologies for prosthetic coatings. The initiative represents a powerful collaboration between two established cooperative entities, MONDRAGON and i+Med, pooling their extensive knowledge, industrial capabilities, and financial resources to forge a new path in high-value medical technology.

NanoSPharm's core mission is to bring to market a novel technology that creates highly biocompatible coatings for prosthetics. This advanced system, based on hyaluronic acid and chitosan nanogels, is designed to enhance osseointegration, provide an antibacterial barrier, and offer self-repairing properties. Future iterations are planned to incorporate controlled release of bioactive substances. The technology, which has garnered global attention as a world first in hydrogel coatings, is protected by robust patents.

The strategic alliance between MONDRAGON, a prominent industrial conglomerate, and i+Med, a specialist in nanohydrogels, positions NanoSPharm for substantial growth. MONDRAGON contributes its deep industrial expertise and established business acumen, while i+Med brings its specialized scientific knowledge and regulatory experience. This synergy is crucial for navigating the complex path from clinical need to market-ready medical device. The venture currently employs a dedicated team of 12 individuals focused on driving this ambitious project forward.

The market for advanced prosthetic technologies is experiencing robust expansion, with projections indicating annual growth rates of approximately 9%. NanoSPharm's technology holds potential applications across a wide spectrum of medical fields, including orthopedic and dental prosthetics, traumatology, maxillofacial surgery, cardiology, urology, and neurosurgery. The company's roadmap includes completing development, securing clinical validation and certifications, and initiating industrialization and international commercialization, with a target launch around 2030.

This launch underscores MONDRAGON's ongoing commitment to fostering future-oriented businesses in high-growth sectors. Pello Rodríguez, President of MONDRAGON, emphasized the project's significance, stating, "NanoSPharm embodies the power of cooperation in translating specialized knowledge into new business ventures. It merges biomedical innovation with industrial strength in a sector with global reach and the potential for significant economic and social impact."

Manu Muñoz, Director of i+Med, highlighted the pivotal role of the partnership in bringing a clinically relevant technology to fruition. "This agreement allows us to take a decisive step in commercializing a technology born from a genuine clinical need," Muñoz commented. "NanoSPharm combines scientific insight, regulatory proficiency, and industrial ambition to improve prosthetic safety and performance." The collaborative spirit is further exemplified by Erreka, a MONDRAGON cooperative, which is already working closely with the project.

The initial funding round of €8.3 million was supported by a strong syndicate of investors, demonstrating confidence in NanoSPharm's innovative approach and market potential. Key participants in this funding include MONDRAGON Ventures, Diana, Portobello, Magnum, GED, Nazca, Miura, Artá, Repsol EV, ProA, Advent, Kibo, Alantra, Nexxus, Ysios, Inveready, Adara, Axon, Bullnet, Realza, Swanlaab, Athos, Asabys, Impact Partners, Lift AM, and Enisa.